SFA Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing oral immune tolerance therapies for psoriasis and other autoimmune and oncology indications using a proprietary deuterated short-chain fatty acid platform.
About SFA Therapeutics, Inc.
SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.
Products
Oral, once-daily deuterated short-chain fatty acid tablet for plaque psoriasis (mild-to-severe), currently in Phase 2 clinical development.
Oral therapy for pancreatic cancer in combination therapy, currently in preclinical stage.
Oral therapy for liver cancer, spanning chronic liver disease to hepatocellular carcinoma, currently in preclinical stage.
Security and compliance
No security details published yet
SFA Therapeutics, Inc. hasn't published certifications or security practices that we could find. Ask their team for audit reports.
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim SFA Therapeutics, Inc.